Loading stock data…
$1.00+0.00 (+0.18%)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Inovio Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.00 with a market capitalization of $103M. Wall Street consensus targets $3.17 (3 analysts), implying a +216.7% move over the next 12 months. The stock is currently 63% below its 52-week high of $2.72, remaining 23.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$21.95M↓ | -$17.48M↑ | -$21.21M↑ | -$23.08M |
| Net Income | — | -$19.68M↓ | $3.76M↑ | -$45.50M↓ | -$23.52M |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...